Sarepta Therapeutics Inc. may find itself on the forefront of endpoint development in Duchenne muscular dystrophy after FDA's accelerated approval of Exondys 51.
With confirmatory trials on the horizon, the company said it is looking beyond potentially using the six-minute walk test to...





